
CLAIMS

1. A compound having formula (**I**):



(**I**)

or a hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein in (**I**):

n is 0 or 1, wherein (i) if n is 0 then X is S, and (ii) if n is 1 then X is CH;

A is selected from the group consisting of hydrogen and C_{1-4} alkyl;

R^1 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, optionally substituted C_{1-4} alkenyl, CO_2R^8, $CONHR^9$, $NHCOR^{10}$, and OR^{11};

or R^1 and A are taken together with the atoms to which they are bound to form an optionally substituted ring having 5-7 ring atoms;

R^2 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, optionally substituted C_{1-4} alkenyl, $NHCOR^{10}$, and OR^{11};

or R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted ring having 5-7 ring atoms optionally containing one or two atoms independently selected from the group consisting of oxygen, sulfur and nitrogen;

R^3 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, and optionally substituted C_{1-4} alkenyl;

or R^2 and R^3 are taken together with the atom to which they are bound to form an optionally substituted ring having 5-7 ring atoms;


R^4, R^5, R^6 and R^7 are independently selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, and OR^{11};

R^8, R^9, R^{10} and R^{11} are each independently selected from the group consisting of hydrogen, optionally substituted C_{1-4} alkyl, and optionally substituted C_{3-7} cycloalkyl; and

m is 0 or 1;

wherein the compound having formula (I) is selected from the group consisting of:

(a) a compound having formula (**II**):




, wherein in (**II**):

R^{12a}, R^{12b}, R^{12c}, and R^{12d} are each independently selected from a group consisting of hydrogen, halogen, and optionally substituted C_{1-4} alkyl; and

n is 0 and X is S;

(b) a compound having formula (**III**):




, wherein in (**III**):

R^{13} and R^{14} are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, and optionally substituted C_{1-4} alkenyl;

or R^{14} and R^{13} are taken together with the atoms to which they are bound to form an optionally substituted ring having 5-7 ring atoms; and

M is selected from the group consisting of O, S, and NH;

(c) a compound having formula (**IV**):




, wherein in (**IV**):

R^{13} and R^{14} are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, and optionally substituted C_{1-4} alkenyl;

or R^{14} and R^{13} are taken together with the atoms to which they are bound to form an optionally substituted ring having 5-7 ring atoms; and

M is selected from the group consisting of O, S, and NH;

(d) a compound having formula (**V**):



(**V**)

, wherein in (**V**):

R^{15a} and R^{15b} are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;


or R^{15a} and R^{15b} are taken together with the atoms to which they are bound to form an optionally substituted ring having 5-7 ring atoms;

Y and Z are each independently selected from the group consisting of CH_2 and O;

p is 0 or 1; and

r is 0 or 1;

(e) a compound having formula (**VI**):




(**VI**)

, wherein in (**VI**):

Y is selected from the group consisting of CH_2 and O; and

q is 0, 1, or 2;

(f) a compound having formula (**VIa**):




(**VIa**)

, wherein in (**VIa**):

Y is selected from the group consisting of CH_2 and O; and

b is 0, 1, or 2;

(g) a compound having formula (**VII**):




(**VII**)

, wherein in (**VII**):

R^{16a}, R^{16b}, R^{16c}, and R^{16d} are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, and OR^{11}; and

n is 0 and X is S;

(h) a compound having formula (**VIIa**):




(**VIIa**)

, wherein in (**VIIa**):

M is selected from the group consisting of O, S, and NH;

(i) a compound having formula (**VIII**):




(**VIII**)

, wherein in (**VIII**):

M is selected from the group consisting of O, S, and NH;


(j) a compound having formula (**IX**):



(IX) , wherein in (**IX**):

R^{17a}, R^{17b}, R^{17c}, and R^{17d} are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-4} alkyl, and OR^{11}; and

(k) a compound having formula (**IXa**):



(IXa) , wherein in (**IXa**):

e is 0, 1, or 2.

2. The compound according to claim 1, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

4,5,6,7-Tetrahydro-benzo[c]thiophene-1-carboxylic acid (4-hydroxy-phenyl)-amide;

4,5,6,7-Tetrahydro-benzo[c]thiophene-1-carboxylic acid phenylamide;

4,5,6,7-Tetrahydro-benzo[c]thiophene-1-carboxylic acid (4-fluoro-phenyl)-amide;

4,5,6,7-Tetrahydro-benzo[c]thiophene-1-carboxylic acid (3-methoxy-phenyl)-amide;

2,3-Dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid (3-trifluoromethyl-phenyl)-amide;

2,3-Dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid (3-chloro-phenyl)-amide:

2,3-Dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid phenylamide;

2,3-Dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid (3-iodo-phenyl)-amide;

Benzo[b]thiophene-3-carboxylic acid (3-chloro-phenyl)-amide;

2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (3-chloro-phenyl)-amide;

2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (3,5-dichloro-phenyl)-amide;

2,3-Dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid (3,4-difluoro-phenyl)-amide;

Benzo[1,3]dioxole-4-carboxylic acid (3-chloro-phenyl)-amide;

2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (3-fluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-fluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (3-trifluoromethoxy-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (2-fluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-bromo-2-fluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (2,5-difluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (3,4-difluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (2,4-difluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (3,4-dichloro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (2-chloro-4-fluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-chloro-2-fluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (2,3,4-trifluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (2,4,6-trifluoro-phenyl)-amide;
2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-chloro-3-fluoro-phenyl)-amide;
3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-phenyl)-amide;
3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3,4-difluoro-phenyl)-amide;
3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide;
5,6,7,8-Tetrahydro-naphthalene-1-carboxylic acid (4-chloro-3-fluoro-phenyl)-amide;
5,6,7,8-Tetrahydro-naphthalene-1-carboxylic acid (3,4-difluoro-phenyl)-amide;
2,3-Dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid (3-iodo-phenyl)-amide;
2-(3-chlorophenyl)-3,4-dihydroisoquinolin-1(2H)-one;
N-(2,4,6-trifluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide;
5,6,7,8-Tetrahydro-naphthalene-1-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide;
N-(3,4-difluorobenzyl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide;
N-(4-phenoxyphenyl)-2,3-dihydrothieno[3,4-b][1,4]dioxine-5-carboxamide;
N-(3-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide;
and any pharmaceutically acceptable salts, hydrates or solvates thereof.

3. A composition comprising an effective amount of at least one compound according to claim 1 or 2.

4. The composition according to claim 3, further comprising at least one excipient.

5. An effective amount of at least one compound according to claim 1 or 2 for use in the treatment or prevention of HBV infection.

6. The compound of claim 5, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.

7. Use of an effective amount of at least one compound according to claim 1 or 2 in the manufacture of a medicament for the treatment or prevention of HBV infection.

8. Use of an effective amount of at least one compound according to claim 1 or 2, together with at least one pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment or prevention of HBV infection.

9. Use of an effective amount of at least one compound according to claim 1 or 2 in the manufacture of a medicament for the treatment or prevention of disease or conditions associated with HBV infection.

10. The use of claim 9, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.